Verrica Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
10 NORTH HIGH STREET, WEST CHESTER, PA, 19380
Mailing Address
10 NORTH HIGH STREET, WEST CHESTER, PA, 19380
Phone
484-453-3300
Fiscal Year End
1231
EIN
463137900
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 29, 2026 | View on SEC |
| 3 Initial insider ownership report | January 26, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 30, 2025 | View on SEC |
| 3 Initial insider ownership report | December 30, 2025 | View on SEC |
| 3 Initial insider ownership report | December 30, 2025 | View on SEC |
| 8-K Current report of material events | December 30, 2025 | View on SEC |
| 4 Insider stock transaction report | December 30, 2025 | View on SEC |
Annual Reports
10-K
March 11, 2026
- FDA approval of YCANTH in July 2023, marking the first FDA-approved treatment for molluscum contagiosum.
- Successful initial commercial launch of YCANTH in September 2023, generating $5.5 million in net product sales.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.